

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to the Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: October 17, 2002

By: Kay L. Gaviglio

Kay L. Gaviglio

PATENT
Docket No. GC571-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:

Davis et al.

Serial No.: 09/556,466

Filed: April 21, 2000

For: **SPECIFICALLY TARGETED CATALYTIC
ANTAGONISTS AND USES THEREOF**

Group Art Unit: 1652

Examiner: Patterson, Charles L. Jr.

Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action mailed April 17, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the present amendment and remarks. This response is considered timely. A petition for a three month extension of time accompanies this communication.

IN THE SPECIFICATION

Please make the following changes (a marked-up copy is attached herein):

Please replace the paragraph found at page 4, lines 9-14, with the following:

In a particularly preferred embodiment the enzyme is a *Bacillus lentus* subtilisin (SBL). In preferred embodiments, the cysteine is substituted for an amino acid in a subtilisin, where the amino acid corresponds to a reference residue in a *Bacillus lentus* subtilisin, where the reference residue is at or near a residue selected from the group consisting of residue 156, residue 166, residue 217, residue 222, residue 62, residue 96, residue 104, residue 107, residue 189, and residue 209.

16/B
M.G.
10/31/02